Maria T. Voso

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 269 publications

FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies.

FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies.

Journal: Cancers

Published: July 14, 2026

Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial.

Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial.

Journal: American journal of hematology

Published: May 25, 2026

De novo JAK2-mutated acute myeloid leukaemia: Clinical outcomes and molecular features.

De novo JAK2-mutated acute myeloid leukaemia: Clinical outcomes and molecular features.

Journal: British journal of haematology

Published: April 23, 2026

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Journal: Blood advances

Published: April 07, 2026

Molecular and clinical analyses of c-CBL mutations affecting tyrosine 371 in myelodysplastic and proliferative disorders.

Molecular and clinical analyses of c-CBL mutations affecting tyrosine 371 in myelodysplastic and proliferative disorders.

Journal: Leukemia

Published: April 02, 2026

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Journal: HemaSphere

Published: February 23, 2026

Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Journal: Leukemia

Published: February 05, 2026

A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.

A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.

Journal: Cancers

Published: January 23, 2026

An Italian cartography of VEXAS-related thrombosis.

An Italian cartography of VEXAS-related thrombosis.

Journal: HemaSphere

Published: January 17, 2026

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: The Lancet. Haematology

Published: January 12, 2026

A case of T-prolymphocytic leukemia harboring RAS mutation.

A case of T-prolymphocytic leukemia harboring RAS mutation.

Journal: Annals of hematology

Published: December 31, 2025

Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.

Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.

Journal: Haematologica

Published: December 23, 2025

Showing 1-12 of 269

Last Updated: 09/26/2026